Milestone cancer vaccine success leaves hard questions unanswered

Messenger RNA vaccine from Merck and Moderna slashes risk of melanoma's return, but why remains unclear.

Authors

Publication Details

Journal
Science
Published
2026-10-29
DOI
https://doi.org/10.1126/science.aen6356
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Milestone cancer vaccine success leaves hard questions unanswered

Jocelyn Kaiser
1 links
Science
Cancer Immunotherapy and Biomarkers
article

Milestone cancer vaccine success leaves hard questions unanswered

Jocelyn Kaiser
article en

Abstract

Messenger RNA vaccine from Merck and Moderna slashes risk of melanoma's return, but why remains unclear.

ScienceVol. 394(6823)
Good health and well-being
Openalex Percentile: Top 16%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Milestone cancer vaccine success leaves hard questions unanswered — Jocelyn Kaiser · Science (2026) | TGRS Research Map | TGRS